Protagenic Therapeutics, Inc.\new (OTC: PTIX), an SEC filer in Pharmaceutical Preparations, closed at $1.11, +22.0%, on 2026-08-28, with a market cap of $2M as of 2026-08-27 and a return on equity of -236.1%. Institutional ownership, earnings history and filed financials are on the tabs below.
Returns use ADJUSTED closes (splits + dividends).
Volume as VALUE TRADED — close × volume, in USD.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | PTIX | SPY | Δ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 · ytd | −63.4% | −2.3% | +45.8% | +29.8% | −38.3% | −27.8% | −54.1% | +516.7% | — | — | — | — | −14.6% | +13.4% | −28.0pp |
| 2025 | −24.7% | −17.3% | −36.0% | +14.8% | +22.8% | −5.2% | −19.5% | +22.4% | −4.7% | −25.1% | −17.1% | −39.0% | −81.0% | +17.7% | −98.8pp |
| 2024 | −4.0% | +10.5% | +66.7% | −21.3% | −4.1% | −31.4% | −21.5% | −14.6% | +3.5% | +4.4% | −9.9% | −16.9% | −50.5% | +24.9% | −75.4pp |
| 2023 | +35.0% | −20.3% | +0.5% | +8.1% | +6.4% | +2.0% | +6.0% | −11.7% | −3.2% | −57.8% | −3.5% | +32.0% | −38.1% | +26.2% | −64.3pp |
| 2022 | −18.4% | −17.7% | −12.4% | +0.4% | −7.0% | −4.8% | −18.5% | +26.3% | −23.4% | −0.2% | −6.8% | −24.7% | −71.1% | −18.2% | −52.9pp |
| 2021 | +295.2% | +36.1% | +3.0% | −61.2% | −1.3% | +29.1% | −25.0% | −2.3% | −11.4% | +0.5% | +0.0% | −26.3% | +31.9% | +28.7% | +3.2pp |
| 2020 | +0.0% | +20.6% | −31.8% | +7.8% | +0.0% | −6.4% | +0.0% | +0.0% | +4.3% | −5.7% | −8.7% | +0.0% | −25.5% | +18.3% | −43.9pp |
| 2019 | +15.0% | −2.2% | −11.1% | +0.0% | −25.0% | — | +0.0% | +0.0% | −6.7% | +42.9% | +0.0% | −29.5% | −29.5% | +31.2% | −60.7pp |
| 2018 · part | −20.0% | — | — | — | — | — | +10.8% | +28.2% | −20.0% | +0.0% | +0.0% | — | −9.1% | −4.6% | −4.5pp |
| 2017 | −35.3% | −62.0% | +15.8% | — | −9.1% | +0.0% | — | — | −12.5% | — | — | +25.7% | −71.5% | +21.7% | −93.3pp |
Month-end over prior month-end; a blank cell is no return.
Basis. PTIX and SPY are on DIFFERENT bases — one includes dividends, the other doesn't, so the Δ column flatters the dividend-including side.
End-of-day closes; a “ytd” or “part” year is not a full year.
| Month | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Years ⓘ | 16 | 16 | 16 | 15 | 16 | 15 | 16 | 15 | 15 | 14 | 14 | 14 |
| Positive ⓘ | 44% | 31% | 44% | 47% | 31% | 27% | 19% | 47% | 27% | 43% | 7% | 21% |
| Median | −0.4% | −3.4% | −4.5% | +0.0% | −0.7% | −6.4% | −19.0% | +0.0% | −10.0% | −0.1% | −7.8% | −25.5% |
| Best | +800.0% | +252.1% | +200.0% | +29.8% | +100.0% | +37.9% | +22.2% | +516.7% | +150.0% | +100.0% | +10.0% | +61.6% |
| Worst | −63.4% | −62.0% | −58.1% | −66.7% | −38.3% | −82.3% | −54.5% | −47.4% | −50.0% | −57.8% | −85.0% | −96.6% |
| vs SPY ⓘ | −1.5pp | −6.8pp | −10.4pp | −1.9pp | −3.6pp | −8.2pp | −22.3pp | +1.7pp | −8.3pp | −4.9pp | −12.7pp | −24.1pp |
182 monthly observations · 2010–2026 · benchmark SPY
